Propanc Biopharma (NASDAQ:PPCB) to Buyback $5.00 million in Outstanding Shares

Propanc Biopharma (NASDAQ:PPCB) declared that its board has initiated a stock repurchase program on Thursday, June 11th, RTT News reports. The company plans to buyback $5.00 million in outstanding shares. This buyback authorization permits the company to buy up to 162.3% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Propanc Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Propanc Biopharma Price Performance

Shares of PPCB stock traded up $1.08 during trading hours on Thursday, reaching $2.43. The company had a trading volume of 174,239,764 shares, compared to its average volume of 65,234. The company has a 50 day moving average of $2.27 and a 200 day moving average of $7.23. The firm has a market cap of $5.54 million, a price-to-earnings ratio of -0.10 and a beta of 3.48. Propanc Biopharma has a 1-year low of $1.30 and a 1-year high of $270.25.

Propanc Biopharma Company Profile

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.